AI assistant
Sending…
Tango Therapeutics, Inc. — Director's Dealing 2024
Nov 19, 2024
32459_dirs_2024-11-18_517bc51f-1270-4cc7-af17-c7d351446ad5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Tango Therapeutics, Inc. (TNGX)
CIK: 0001819133
Period of Report: 2024-11-14
Reporting Person: Rothenberg Mace (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-11-14 | Common Stock | P | 10000 | $3.62 | Acquired | 21250 | Direct |
| 2024-11-18 | Common Stock | P | 10000 | $3.78 | Acquired | 31250 | Direct |
More from Tango Therapeutics, Inc.
Share Issue/Capital Change
2026
Jun 8
Regulatory Filings
2026
Jun 8
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 4
Board/Management Information
2026
May 13
Board/Management Information
2026
May 8
Annual Report
2026
Apr 17
Proxy Solicitation & Information Statement
2026
Apr 17
Board/Management Information
2026
Apr 15
Director's Dealing
2026
Mar 28
Regulatory Filings
2026
Mar 25